Antibiotics Market Set To Reach US$ 58.4 Billion By 2032

Trishita Deb
Trishita Deb

Updated · Oct 14, 2024

SHARE:

Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
close
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Introduction

Global Antibiotics Market size is expected to be worth around USD 58.4 Billion by 2032 from USD 42.4 Billion in 2023, growing at a CAGR of 3.7% during the forecast period from 2023 to 2032.

Bacterial infections are a major global health concern, being responsible for about one in every eight deaths worldwide. This high impact is partly due to many bacteria developing resistance to commonly used antibiotics, rendering treatments less effective. The Centers for Disease Control and Prevention (CDC) estimates that in the U.S. alone, the healthcare costs associated with treating infections from six major drug-resistant bacteria exceed USD 4.6 billion annually.

Antibiotics, which are drugs used to treat bacterial infections, are crucial in both human and veterinary health. They work by killing bacteria or preventing their growth. Available in various forms such as tablets, injections, and creams, antibiotics are essential for treating serious infections like urinary tract infections and strep throat. However, their effectiveness is threatened by antibiotic resistance, which occurs when bacteria evolve to withstand the drugs designed to kill them.

To combat this, the World Health Organization (WHO) measures antibiotic use in Defined Daily Doses (DDD) per 1,000 inhabitants per day, allowing for standardized global tracking and comparison. The WHO’s AWaRe classification system categorizes antibiotics into three groups Access, Watch, and Reserve to guide optimal usage and reduce the risk of resistance. This system aims to increase the use of ‘Access’ antibiotics, which are deemed most effective and safe, while minimizing the use of ‘Watch’ and ‘Reserve’ categories known for higher resistance risks.

Managing antibiotic use is vital to controlling antimicrobial resistance, one of the biggest threats to global health. Effective stewardship and accurate diagnosis are key to ensuring antibiotics remain a powerful tool against bacterial infections.

global antibiotics market size

Key Takeaways

  • Market Size: Global Antibiotics Market size is expected to be worth around USD 58.4 Billion by 2032 from USD 42.4 Billion in 2023.
  • Market Growth: The growing at a CAGR of 3.7% during the forecast period from 2023 to 2032.
  • Drug Class Analysis: The penicillin segment accounted for the largest market revenue share of 24.5% in 2022
  • Application Analysis: The Respiratory Infections Segment is Expected to Show Lucrative Growth During the Forecast Period
  • Spectrum of Activity Analysis: The Broad-Spectrum Antibiotic Held the Largest Market Growth.
  • Distribution Analysis: The hospital pharmacy segment dominated the market with the highest revenue share of 28% in 2022.
  • Regional Analysis: Asia-Pacific accounted for a significant antibiotics market revenue share of 45%.

Antibiotics Statistics

Global Antibiotic Consumption Trends:

  • Antibiotic consumption globally increased by 65% between 2000 and 2015.
  • Projected increase in antibiotic consumption in animals by 11.5% from 2017 to 2030.

Antimicrobial Resistance (AMR) and Antibiotic Stewardship:

  • High-income countries are seeing a leveling off of AMR due to improved antibiotic stewardship.
  • Rising trends of inappropriate antibiotic use in low- and middle-income countries.

U.S. Antibiotic Prescribing and Stewardship:

  • 30-50% of antibiotic prescriptions are deemed unnecessary or inappropriate in the U.S..
  • In 2022, outpatient antibiotic prescriptions amounted to approximately 236.4 million.
  • Over 2.8 million antimicrobial-resistant infections occur annually in the U.S., resulting in more than 35,000 deaths.
  • The CDC reports a reduction in outpatient antibiotic prescriptions from 20% in 2011 to 10% in 2020.

Antibiotic Use in Specific Settings:

  • Long-term care facilities in the U.S. are increasingly adopting antibiotic stewardship programs.
  • Advanced practice clinicians are responsible for about 40% of antibiotic prescriptions in the U.S..

Geographical and Setting-Specific Variations:

  • Highest rates of antibiotic prescribing are found in the southern United States, influenced by non-clinical factors such as regional prescribing habits.
  • European antibiotic consumption rates vary, with some regions exceeding 20 defined daily doses per 1,000 inhabitants per day.

Impact of Stewardship Programs:

  • CDC initiatives have reduced inappropriate antibiotic prescriptions from 47.8% to 33.3% in targeted U.S. settings.
  • Antibiotics are most commonly prescribed for respiratory conditions in the U.S., with a significant portion deemed unnecessary.

Emerging Trends

  • Increasing integration of health equity principles into antibiotic stewardship and resistance programs to address disparities in access and outcomes.
  • Growing adoption of antibiotic stewardship programs in long-term care facilities, with CDC reporting expansions in core elements of stewardship across various healthcare settings.
  • Persistent regional variations in antibiotic prescribing practices, with certain areas like the Southern United States showing higher rates of inappropriate prescriptions.
  • Expansion of the CDC’s Antimicrobial Resistance Laboratory Network, which is enhancing the capacity to detect and respond to resistant infections across the U.S..
  • Implementation of the U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria, aiming to reduce the prevalence of resistant bacteria through coordinated public health actions.
  • Shifts in antibiotic prescribing trends during the COVID-19 pandemic, with a notable increase in the use of specific antibiotics like azithromycin during peak periods.
  • Utilization of wastewater surveillance to monitor the spread of antibiotic-resistant genes as an indicator of community health risks.
  • Increasing emphasis on prevention products, including vaccines and novel therapeutics, to reduce reliance on antibiotics and limit the spread of resistant infections.
  • Growing focus on global coordination and policy-making to combat antimicrobial resistance, highlighted by international health organizations like the World Health Organization.
  • Enhanced public health training and investments in infection prevention and control measures to mitigate the spread of antimicrobial resistance.

Use Cases

  • Treatment of Community-Acquired Pneumonia: Commonly prescribed antibiotics include ceftriaxone and azithromycin, especially noted during peaks like the COVID-19 pandemic.
  • Outpatient Settings: Antibiotics are prescribed for a variety of conditions in outpatient settings, with significant efforts to ensure prescriptions are necessary to combat antimicrobial resistance.
  • Inpatient Settings: Used for severe infections requiring hospitalization, such as certain pneumonias and other bacterial infections.
  • Long-Term Care Facilities: Addressing infections in elderly populations, where stewardship programs are crucial to monitor and guide appropriate use.
  • Urgent Care Centers: Focused interventions to reduce inappropriate prescriptions, especially for conditions like acute respiratory infections.
  • Veterinary Medicine: Used to treat and prevent bacterial infections in animals, paralleling human medical use but under different regulatory standards.
  • Agriculture: Employed to prevent diseases in livestock and increase feed efficiency, though this use is controversial due to concerns about antibiotic resistance.
  • Surgery and Critical Care: Essential for preventing infections in surgical sites and supporting recovery in intensive care units.
  • Dental Procedures: Used prophylactically to prevent infections during and after invasive dental procedures, especially in patients at risk of infective endocarditis.
  • Newborn and Maternal Health: Critical for preventing and treating infections in newborns and during childbirth.

Conclusion

The escalating challenge of antimicrobial resistance underscores the imperative for stringent antibiotic stewardship and optimized use across various settings, from healthcare to agriculture. With antibiotic resistance contributing to significant morbidity and healthcare costs, effective stewardship programs are crucial for curbing inappropriate prescriptions and enhancing treatment outcomes. Global efforts must focus on promoting Access antibiotics to minimize resistance risks and ensuring equitable access to essential medications. Continued surveillance and policy initiatives aimed at combating antibiotic resistance will be vital for maintaining the efficacy of these critical drugs and safeguarding public health.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

SHARE:
Trishita Deb

Trishita Deb

Trishita has more than 8+ years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.

Request a Sample Report
We'll get back to you as quickly as possible